C4 Therapeutics (CCCC) PT Lowered to $22 at UBS
Tweet
Share
E-mailGet Alerts CCCC Hot Sheet
Price: $3.85 -6.1%
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 3
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 3
Join SI Premium – FREE
UBS analyst Colin Bristow lowered the price target on C4 Therapeutics (NASDAQ: CCCC) to $22.00 (from $24.00) while maintaining a Buy rating.
You May Also Be Interested In
- Freedom Broker Downgrades Workday (WDAY) to Hold
- Minimax Group Inc (100:HK) PT Raised to HK$804 at Macquarie
- Zhejiang Sanhua Intelligent Controls (002050:CH) PT Lowered to RMB24.20 at Macquarie
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
